These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25885674)

  • 1. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies.
    Dunne MW; Sahm D; Puttagunta S
    Ann Clin Microbiol Antimicrob; 2015 Apr; 14():19. PubMed ID: 25885674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
    Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
    Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
    Huband MD; Castanheira M; Farrell DJ; Flamm RK; Jones RN; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2016 Jun; 47(6):495-9. PubMed ID: 27211209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin.
    Jones RN; Farrell DJ; Flamm RK; Sader HS; Dunne MW; Mendes RE
    Diagn Microbiol Infect Dis; 2015 May; 82(1):73-7. PubMed ID: 25724854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
    Biedenbach DJ; Ross JE; Fritsche TR; Sader HS; Jones RN
    J Clin Microbiol; 2007 Mar; 45(3):998-1004. PubMed ID: 17215346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
    J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.
    Koeth LM; DiFranco-Fisher JM; McCurdy S
    J Vis Exp; 2015 Sep; (103):. PubMed ID: 26381422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
    Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus.
    Jacob B; Makarewicz O; Hartung A; Brodt S; Roehner E; Matziolis G
    Sci Rep; 2021 Dec; 11(1):23425. PubMed ID: 34873186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
    Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
    N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.
    Sader HS; Mendes RE; Duncan LR; Pfaller MA; Flamm RK
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263077
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Plota M; Papadimitriou-Olivgeris M; Kolonitsiou F; Tsiata E; Spiliopoulou I; Assimakopoulos SF; Marangos M
    J Med Microbiol; 2021 Sep; 70(9):. PubMed ID: 34559042
    [No Abstract]   [Full Text] [Related]  

  • 15. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
    Jones RN; Sader HS; Fritsche TR; Hogan PA; Sheehan DJ
    J Clin Microbiol; 2006 Jul; 44(7):2622-5. PubMed ID: 16825398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains.
    Citron DM; Tyrrell KL; Goldstein EJ
    Diagn Microbiol Infect Dis; 2014 Aug; 79(4):438-40. PubMed ID: 24972854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activity and resistance development profiling of dalbavancin.
    Goldstein BP; Draghi DC; Sheehan DJ; Hogan P; Sahm DF
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1150-4. PubMed ID: 17220411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subinhibitory Dalbavancin Attenuates Exotoxin Production from Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus
    Hobdey SE; Katahira EJ; Dockstader P; Davidson SM; Bond L; Bolz DD; Bryant AE; Stevens DL
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.
    Lepak A; Marchillo K; VanHecker J; Andes D
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7833-6. PubMed ID: 26392492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
    Aktaş G; Bozdoğan B; Derbentli S
    Mikrobiyol Bul; 2012 Jul; 46(3):359-65. PubMed ID: 22951648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.